G01N 33/57575
Involving oncogenic proteins
Official title: {involving oncogenic proteins}
G01N33/57575 (Involving oncogenic proteins) appears on 296 US grants and 513 published applications in this corpus.
Search patents in G01N- Granted patents
- 296
- Published applications
- 513
- Assignees
- 290
- Inventors
- 972
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 5 | 0 |
| 1989 | 1 | 0 |
| 1990 | 6 | 0 |
| 1991 | 5 | 0 |
| 1992 | 2 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 7 | 0 |
| 1998 | 8 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 0 |
| 2002 | 2 | 10 |
| 2003 | 3 | 15 |
| 2004 | 0 | 14 |
| 2005 | 4 | 13 |
| 2006 | 1 | 14 |
| 2007 | 6 | 9 |
| 2008 | 2 | 18 |
| 2009 | 6 | 9 |
| 2010 | 5 | 17 |
| 2011 | 5 | 14 |
| 2012 | 6 | 15 |
| 2013 | 3 | 10 |
| 2014 | 8 | 31 |
| 2015 | 7 | 34 |
| 2016 | 19 | 34 |
| 2017 | 12 | 49 |
| 2018 | 19 | 20 |
| 2019 | 20 | 38 |
| 2020 | 21 | 29 |
| 2021 | 15 | 32 |
| 2022 | 18 | 28 |
| 2023 | 12 | 23 |
| 2024 | 22 | 17 |
| 2025 | 10 | 14 |
| 2026 | 5 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- T cell receptors recognizing HLA-CW8 restricted mutated KRAS7 Jul 2026US 12,673,981 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Method for the treatment or prophylaxis of cancer by targeting the extracellular portion of keratin 14 (KRT14) residing on cancer cells7 Jul 2026US 12,673,985 B2Hudson Institute of Medical Research
- HLA class II-restricted DRB T cell receptors against RAS with G12D mutation16 Jun 2026US 12,655,193 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes19 May 2026US 12,630,883 B2Japanese Foundation for Cancer Research
- Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation3 Mar 2026US 12,565,537 B2MUSC Foundation for Research Development
- Hla class ii-restricted drb t cell receptors against ras with g12d mutation10 Sep 2026US 2026/0265338 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer6 Aug 2026US 2026/0226193 A1NomoCan Pharmaceuticals LLC
- Method of detecting disease-associated markers in a liquid biopsy sample using extracellular vesicles6 Aug 2026US 2026/0227404 A1The General Hospital Corporation
- Compositions and methods for the treatment and diagnosis of cancers associated with surface k-ras11 Jun 2026US 2026/0158070 A1University of Maryland, Baltimore
- Methods for detecting aggressive prostate cancer4 Jun 2026US 2026/0155258 A1Minomic International Ltd.
Most cited
By later US patents
- Transgenic non-human mammals531US 4,736,866 APresident and Fellows of Harvard College · 1988
- Determination of status in neoplastic disease237US 4,968,603 AThe Regents of the University of California · 1990
- Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto180US 5,480,968 AThe United States of America as represented by the Department of Health and Human Services · 1996
- Methods and apparatus for the quantitation of nuclear protein164US 5,202,931 ACell Analysis Systems, Inc. · 1993
- DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor146US 5,183,884 AUnited States of America · 1993